Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.34 |
| ▸ | OTUD7B | Q6GQQ9 | 12/20 | 0.34 |
| ▸ | CMA1 | P23946 | 2/20 | 0.32 |
| ▸ | AHR | P35869 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3594228 | 0.86 | BRD4 (0.35) | PDK2PDK4OTUD7BAHRCYP1A2 | |
| SCHEMBL23685921 | 0.81 | CYP3A4 (0.45) | OTUD7BCYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL30645893 | 0.79 | ESR2 (0.39) | OTUD7BCYP3A4 | |
| SCHEMBL30100708 | 0.79 | CYP1A2 (0.44) | OTUD7BCYP1A2CYP2C19 | |
| SCHEMBL23675075 | 0.79 | CYP1A2 (0.44) | OTUD7BCYP1A2CYP2C19 | |
| SCHEMBL1709821 | 0.79 | CA9 (0.53) | PDK2PDK4OTUD7BCA9 | |
| SCHEMBL16896923 | 0.77 | OTUD7B (0.55) | OTUD7BCYP3A4EIF2AK2PGR | |
| SCHEMBL13382920 | 0.77 | HTR6 (0.38) | PDK2PDK4OTUD7B | |
| SCHEMBL6220027 | 0.74 | PDK2 (0.48) | PDK2PDK4OTUD7BAHRPOLB | |
| SCHEMBL30100699 | 0.74 | PDK2 (0.48) | PDK2PDK4OTUD7BAHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | PDK2 3637/4885PDK4 3828/4885OTUD7B 2816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.